Not Approved
This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.
No Human Data
No human exposure data has been identified for this substance. All available evidence comes from animal models or in vitro studies. Safety in humans is completely unknown.
Evidence visual
FOXO4-DRI evidence and risk matrix
advanced researcher fit
Evidence
Tier C
Risk
high
Regulatory
not approved
WADA
none
FDA
unknown
Route
subcutaneous
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
FOXO4-DRI is a D-retro-inverso peptide designed to block the FOXO4-p53 interaction, inducing apoptosis in senescent cells. The concept has been validated preclinically but there is no standard human therapeutic framework. Mouse studies use 5 mg/kg IP on every-other-day schedules. Safety in humans is unknown; this is a high-risk category from a platform standpoint.
Decision path
Where FOXO4-DRI fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether FOXO4-DRI belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Blocks FOXO4-p53 interaction, inducing apoptosis in senescent cells (preclinical senolytic concept).
subcutaneous
Mouse: 5 mg/kg IP every other day (limited administrations).
Preclinical: selective elimination of senescent cells. No proven human benefit.
Mouse outcomes assessed over days to weeks, depending on tissue model.
No human data.
Unknown in humans; high-risk category.
Unknown; do not propose combinations.
Cost at a glance
Typical cycle cost
€96.35
Estimated monthly
€96.35
Protocol style
Insufficient evidence
Insufficient evidence
Estimate confidence
High confidence
Assumes roughly 6 mg–12 mg per cycle, using 1 tracked affiliated listing.
Preclinical senolytic work exists, but there is no reliable human cycle standard.
Known Interactions
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for FOXO4-DRI.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.